Literature DB >> 15140115

Is the incidence and prevalence of inhibitors greater with recombinant products? Yes.

L M Aledort1.   

Abstract

Mesh：

Substances：

Year:  2004        PMID： 15140115     DOI： 10.1111/j.1538-7836.2004.00731.x

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN： 1538-7836            Impact factor:   5.824


× No keyword cloud information.
  9 in total

1.  Plasma-derived versus recombinant factor VIII concentrates for the treatment of haemophilia A: plasma-derived is better.

Authors:  Pier Mannuccio Mannucci
Journal:  Blood Transfus       Date:  2010-10       Impact factor: 3.443

Review 2.  Alloantibodies to therapeutic factor VIII in hemophilia A: the role of von Willebrand factor in regulating factor VIII immunogenicity.

Authors:  Johannes Oldenburg; Sébastien Lacroix-Desmazes; David Lillicrap
Journal:  Haematologica       Date:  2015-02       Impact factor: 9.941

3.  Quantitation of anti-factor VIII antibodies in human plasma.

Authors:  Jolanta Krudysz-Amblo; Behnaz Parhami-Seren; Saulius Butenas; Kathleen E Brummel-Ziedins; Edward D Gomperts; Georges E Rivard; Kenneth G Mann
Journal:  Blood       Date:  2009-01-14       Impact factor: 22.113

Review 4.  Factor VIII inhibitors: risk factors and methods for prevention and immune modulation.

Authors:  Ai Hong Zhang; Jonathan Skupsky; David W Scott
Journal:  Clin Rev Allergy Immunol       Date:  2009-10       Impact factor: 8.667

Review 5.  Past, present and future of hemophilia: a narrative review.

Authors:  Massimo Franchini; Pier Mannuccio Mannucci
Journal:  Orphanet J Rare Dis       Date:  2012-05-02       Impact factor: 4.123

Review 6.  Immune Responses to Plasma-Derived Versus Recombinant FVIII Products.

Authors:  Flora Peyvandi; Syna Miri; Isabella Garagiola
Journal:  Front Immunol       Date:  2021-01-22       Impact factor: 7.561

7.  Plasma-derived FVIII/VWF complex shows higher protection against inhibitors than isolated FVIII after infusion in haemophilic patients: A translational study.

Authors:  Maria Isabel Bravo; Alba Pérez; Aida Raventós; Salvador Grancha; Juan Ignacio Jorquera; Nora Viviana Butta; Maria Teresa Álvarez-Román; Montserrat Costa; Todd Willis; Victor Jiménez-Yuste
Journal:  Haemophilia       Date:  2022-06-02       Impact factor: 4.263

8.  Product type and other environmental risk factors for inhibitor development in severe hemophilia A.

Authors:  Flora Peyvandi; Isabella Garagiola
Journal:  Res Pract Thromb Haemost       Date:  2018-04-10

Review 9.  Current concepts in the prevention of pathogen transmission via blood/plasma-derived products for bleeding disorders.

Authors:  Giovanni Di Minno; Carlo Federico Perno; Andreas Tiede; David Navarro; Mariana Canaro; Lutz Güertler; James W Ironside
Journal:  Blood Rev       Date:  2015-07-20       Impact factor: 8.250
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.